

Anti-amyloid therapy for Alzheimer's disease: the time has come

Chairs : Katsuya Urakami

Department of Dementia Prevention, School of Health Science, Faculty of Medicine, Tottori University, Japan

Atsushi Iwata

Tokyo Metropolitan Geriatric Hospital, Japan

HT-01-1 Gantenerumab in early symptomatic Alzheimers Disease

Janice W. Smith

Roche Products Ltd, UK

HT-01-2 TRAILBLAZER-ALZ-4: Comparing donanemab to aducanumab in early, symptomatic Alzheimer's disease

Stephane Epelbaum

Eli Lilly and Company, USA

HT-01-3 Development of Therapeutics in Alzheimer's disease

Yasuo Toda

Biogen, Japan

HT-01-4 CLARITY AD: A Global Phase 3 Trial of Lecanemab in Early Alzheimer's Disease

Jin Zhou

Eisai, Inc., USA

Nominal supported by: Japan Society for Dementia Research

Cutting edge of development in stroke therapy**How does the researcher achieve the translational research?**

Chairs : Tetsuro Ago

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan

Ryota Tanaka

Stroke Center and Division of Neurology, Department of Medicine, Japan

HT-02-1 Development of novel thrombolytic agents using SMTP

Kuniyasu Niizuma

Department of Neurosurgical Engineering and Translational Neuroscience, Graduate School of Biomedical Engineering, Tohoku University, Japan / Department of Neurosurgical Engineering and Translational Neuroscience, Tohoku University Graduate School of Medicine, Japan / Department of Neurosurgery, Tohoku University Graduate School of Medicine, Japan

HT-02-2 Development of an efferocytosis drug for the treatment of cerebral ischemia

Akira Shibuya

Center for Innovative Drug Discovery and Faculty of Medicine, University of Tsukuba, Japan

HT-02-3 Targeting the moyamoya disease susceptibility gene RNF213 as a therapeutic strategy for stroke

Masafumi Ihara

Department of Neurology, National Cerebral and Cardiovascular Center, Japan

**HT-02-4 Development of vaccines in ischemic stroke
- Focusing on anti-thrombotic vaccines against S100A9**

Munehisa Shimamura

Department of Gene & Stem Cell Regenerative Therapy, Osaka University, Japan / Department of Neurology, Osaka University, Japan

HT-03 Hot Topics 03

Web En

June 1 (Thu) 8 : 00 ~ 9 : 30 Room 02 (Makuhari Messe International Conference Hall 2F International Conference Room)

All Roads Lead to Cure

- from basic researches towards clinical trials for ataxia

Chairs : Yoshio Ikeda

Department of Neurology, Gunma University Graduate School of Medicine,
Japan

Yuji Takahashi

National Center of Neurology and Psychiatry, Japan

HT-03-1 The ATXN2 complex as a therapeutic target for spinocerebellar ataxias and ALS

Stefan M. M. Pulst

University of Utah, USA

HT-03-2 Therapeutic approaches for non-coding repeat expansion diseases
Yoshio Ikeda

Department of Neurology, Gunma University Graduate School of Medicine, Japan

HT-03-3 Pathophysiology and therapeutic strategies for spinocerebellar ataxia type 42

Fumiaki Tanaka

Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan

HT-03-4 Multiple system atrophy: from genetics to clinical trials

Shoji Tsuji

International University of Health and Welfare, Japan / Department of Neurology, The University of Tokyo Hospital, Japan

MS brain inflammation; to B or not to B that is the question

Chairs : Kazumasa Yokoyama

Tousei center for neurological diseases, Japan

Noriko Isobe

Department of Neurology, Graduate School of Medical Sciences, Kyushu University, Japan

HT-04-1 Brain Inflammation in MS; Should It be B-Cell therapy?

From the viewpoint of T cells

Kazumasa Yokoyama

Tohsei center for neurological diseases, Japan / Department of Neurology Juntendo University, Japan

HT-04-2 Contribution of B cells in MS brain inflammation

Koji Shinoda

Department of Neurology, Iizuka Hospital, Japan / Department of Neurology, Kyushu University, Japan

HT-04-3 Neuroinflammation as therapeutic targets based on innate immune system

Izumi Kawachi

Dept. of Neurology, Brain Research Institute, Niigata University, Japan / Medical Education Center, Niigata University School of Medicine, Japan

HT-04-4 Glial CNS inflammation and its treatment

Hideyuki Takeuchi

Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan

**Disease-modifying treatment of PD:
What is the rate-limiting factor of drug discovery?**

Chairs : Atsushi Takeda

National Hospital Organization Sendai Nishitaga Hospital, Japan

Noriko Nishikawa

Department of Neurology, Juntendo University School of Medicine, Japan

**HT-05-1 Synuclein-targeting therapies in PD:
what do we know and where are we headed?**

Takafumi Hasegawa

Division of Neurology, Department of Neuroscience & Sensory Organs, Tohoku University Graduate School of Medicine, Japan

HT-05-2 What triggers Parkinson's disease?

Approach from familial form for drug discovery

Yutaka Oji

Department of Neurology, Juntendo University School of Medicine, Japan

HT-05-3 Updates of disease biomarkers of Parkinson's disease

Chin-Hsien Lin

National Taiwan University Hospital, Taiwan

HT-05-4 Issues in clinical trials of disease-modifying therapies for Parkinson's disease

Thomas Foltynie

UCL Institute of Neurology, UK / National Hospital for Neurology & Neurosurgery, UK

HT-06 Hot Topics 06**Jp**

June 2 (Fri) 8:00 ~ 9:30

Room 11 (Tokyo Bay Makuhari Hall 2F No.3, 4)

Development of the basic research using human brain tissues

Chairs : Masaki Takao

National Center of Neurology and Psychiatry (NCNP) National Center Hospital, Japan

Maya Mimuro

Pathology Division, Mie University Hospital, Japan

HT-06-1 Toward elucidation of neuropathological basis of bipolar disorder

Tadafumi Kato

Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Japan

HT-06-2 Drug transporter study at central nervous system barrier using human postmortem brain

Yasuo Uchida

Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan

HT-06-3 Atomic structures of pathological protein filaments in neurodegenerative diseases

Masato Hasegawa

Tokyo Metropolitan Institute of Medical Science, Japan

HT-06-4 Human Postmortem Brain Study of Tauopathy with a Focus on ALS/PDC in the Kii Peninsula

Satoru Morimoto

Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institution of Gerontology, Japan / Department of Physiology, Keio University School of Medicine, Japan / Department of Oncologic Pathology, Mie University, Japan

Nominal supported by: The Japanese Society of Neuropathology

Migraine: Pathophysiology and the paradigm shift of management

Chairs : Hisaka Igarashi

Headache Care Unit, Department of Internal Medicine, Fujitsu Clinic, Japan

Takao Takeshima

Neurology, Tominaga Hospital, Japan

HT-07-1 Central mechanism in migraine pathogenesis

Mamoru Shibata

Tokyo Dental College Ichikawa General Hospital, Japan

HT-07-2 Peripheral mechanism and key players in migraine

Tsubasa Takizawa

Department of Neurology, Keio University School of Medicine, Japan

HT-07-3 CGRP monoclonal antibodies

Daisuke Danno

Tominaga Hospital Headache Center, Japan

HT-07-4 Migraine and Neuromodulation

Noboru Imai

Department of Neurology / Headache Center, Japanese Red Cross Shizuoka Hospital, Japan

HT-07-5 Management of Migraine

Andrew Blumenfeld

The Los Angeles Headache Center, USA